US › Healthcare

Aldeyra The (ALDX)

US · Healthcare · Biotechnology

$1.55+1.31%

Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue

Net profit

$-3.5M

Profit YoY

+65.2%

EPS

$-0.06

EPS estimate

$-0.12

EPS came in at -0.06 against a street estimate of -0.12 — a beat of 50.0%.

Key statistics

Market cap

$92.3M

Forward P/E

0.0

P/B

2.20

Book value

$0.70

EPS (TTM)

$-0.45

52-week high

$6.17

52-week low

$1.07

50-day MA

$1.82

200-day MA

$3.47

Beta

1.20

Analyst view

Analysts rate Aldeyra The a strong buy (7 buy, 0 hold, 0 sell out of 7) with an average price target of $6.60.

Shareholding

Insiders

3.60%

Institutions

62.68%

Largest institutional holders

Fund	Stake
Knoll Capital Management LP	9.08%
BlackRock Inc	6.24%
Vanguard Group Inc	6.13%
AQR Capital Management LLC	4.69%
Vanguard Capital Management, LLC	3.92%
Kingdon Capital Management LLC	3.57%
683 Capital Management LLC	2.49%
D. E. Shaw & Co LP	2.33%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Aldeyra The — free to start.

Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc UnitedHealth Group Incorporated Merck & Company Inc Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Novo Nordisk A/S Amgen Inc Abbott Laboratories Gilead Sciences Inc

Data updated 2026-08-05.